

THE AMENDMENTS

Clean Version with Changes Incorporated

In the Specification

Please replace the paragraph starting from page 5, line 36 with the following paragraph:

B1
“First fusion partner” refers to an amino acid sequence of or a nucleic acid sequence encoding a human framework or human immunoglobulin variable region in which the native (or naturally-occurring) CDRs are replaced by the CDRs of a donor antibody. The human variable region can be an immunoglobulin heavy chain, a light chain (or both chains), an analog or functional fragments thereof. Such CDRs or CDR regions, located within the variable region of antibodies (immunoglobulins) can be determined by known methods in the art. For example, Kabat et al., [Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987)], disclose rules for locating CDRs. In addition, computer programs are known which are useful for identifying CDR regions/structures.

In the Claims

Please amend Claims 1, 3, 7, 8, 9, 14, and 16 as follows:

class B2
1. (Amended) A fusion protein having binding specificity for human interleukin-4 (IL4) which comprises complementarity determining regions (CDRs) obtained from a non-human neutralizing monoclonal antibody characterized by a dissociation constant equal to or less than 2×10^{-10} M for human IL4, and a first fusion partner.

B3 class
3. (Amended) The fusion protein according to claim 1 wherein said non-human neutralizing monoclonal antibody is 6A1.

B4 class
7. (Amended) The fusion protein according to claim 1 wherein the complementarity determining regions (CDRs) for the heavy chain comprise: